DBV Technologies shares fall sharply: concerns over cash position and new financing
Published
The share price of DBV Technologies has fallen sharply. DBV Technologies is a French biotech company working on medicines for food allergies. The company is listed on the stock exchange, so investors react quickly to news about the company.
The decline has several causes. Investors are concerned about the company's cash position. The cash position is the money a company currently has available. If there is little money, it can become more difficult to continue research and development.
Financing also plays a role. A company can raise money by issuing new shares. This is called a dilutive financing, because existing shareholders then own a smaller part of the company. The value of each share may also fall. For investors, this is an important point in assessing the company.
So far, the available report does not include an official statement from the company. It is therefore not clear how the company will resolve its financial situation. Investors will likely follow the company's announcements in the coming period.
Sources: MarketScreener Nederland
More Netherlands news
- ASE Technology's Revenue Rises in October
- AI company Databricks invests half a billion in the Netherlands
- US midterm elections weigh on tech stocks, Chinese stock market rises
- Doubt over Memphis Depay's international career
- Politics wants investigation into new name for Mariahoeve station
- From Party Line to Government Line: Why Rob Jetten Cannot Say the Same as Prime Minister and Party Leader
- Garmin Cirqa: an activity tracker without a screen
- Achmea Real Estate invests in new healthcare building of Slingeland